metiamiden.
/mᵻˈtʌɪəmʌɪd/, U.S. /məˈtaɪəˌmaɪd/ Pharmacology.
An imidazole derivative that is a selective histamine H2-receptor antagonist, developed as an orally-active inhibitor of gastric acid secretion but found to produce bone marrow suppression; 1-methyl-3-(2-[5-methylimidazol-4-ylmethylthio]ethyl)thiourea, C9H16N4S.
ΘΚΠ
the world > health and disease > healing > medicines or physic > medicines for specific purpose > preparations treating or preventing specific ailments > [noun] > for ulcers
sucralfate1969
metiamide1973
Tagamet1974
cimetidine1975
ranitidine1979
1973 Gut 14 424/1 Metiamide, an analogue of burimamide, has been given intravenously to seven volunteers.
1977 Lancet 10 Sept. 555/2 The bone-marrow toxicity of metiamide might be related to the compound's ability to block the histamine H2-receptor associated with the pluripotent bone-marrow stem cell.
1981 M. C. Gerald Pharmacol. (ed. 2) xxv. 498 Burimamide, ineffective when taken by mouth..,was succeeded in clinical trials by the orally active metiamide; trials were discontinued when metiamide was found to cause agranulocytosis.
1987 Agents & Actions 22 220/2 The TTX [= tetrodotoxin]-resistant responses to histamine were sensitive to mepyramine, but not metiamide.
1996 Gen. Pharmacol. 27 529 The relaxant effect of histamine was abolished by metiamide, but it was not affected by sotalol and atropine.
This entry has been updated (OED Third Edition, December 2001; most recently modified version published online March 2022).
<
n.1973